|
Canada-ON-PETERBOROUGH Azienda Directories
|
Azienda News:
- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
DOI: 10 1001 jamaophthalmol 2024 6555 Abstract Importance: Semaglutide, a glucagonlike peptide-1 receptor agonist (GLP-1RA), has recently been implicated in cases of nonarteritic anterior ischemic optic neuropathy (NAION), raising safety concerns in the treatment of type 2 diabetes (T2D)
- Considerations Regarding Association of Semaglutide and Nonarteritic . . .
To the Editor We commend Hathaway and colleagues 1 on their seminal work describing a potential association between semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), and the development of nonarteritic anterior ischemic optic neuropathy (NAION) 1 While the findings are hypothesis generating, the study has some limitations that
- Disproportionality analysis on semaglutide and nonarteritic anterior . . .
We aimed at obtaining further insights into this safety issue by updating data to December 2024, by expanding coverage (including tirzepatide, across therapeutic indications), critically considering expected biases and confounders in the real-life safety assessment of semaglutide
- Semaglutide and nonarteritic anterior ischemi | EurekAlert!
About The Study: The results of this study suggest a modest increase in the risk of nonarteritic anterior ischemic optic neuropathy among individuals with type 2 diabetes associated with
- Semaglutide Associated With Modest Increased Risk of Nonarteritic . . .
Results of a study published in JAMA Ophthalmology showed a modest increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) for patients with type 2 diabetes who are using semaglutide However, the investigators stated that further research into this area is needed 1
- Semaglutide Use Slightly Increase Optic Neuropathy Risk - Ophthalmology . . .
Published online February 20, 2025 doi: 10 1001 jamaophthalmol 2024 6555 Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy
- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
See commentary "Semaglutide and Risk of NAION-Additional Insights " with doi: 10 1001 jamaophthalmol 2025 0005 This cohort study investigates the association between semaglutide use and nonarteritic anterior ischemic optic neuropathy
- Nonarteritic Anterior Ischemic Optic Neuropathy Increased With . . .
(HealthDay News) — For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION), according to a
- Semaglutide Tied to Small Risk of Potentially Blinding Eye Condition
Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 diabetes The risk was more modest than previously reported Using the specific
- What the diabetologist needs to know about the risk of non-arteritic . . .
Aim: Recent findings have raised concern about a potential association between semaglutide use and non-arteritic anterior ischaemic optic neuropathy (NAION), a rare form of permanent vision loss
|
|